Clinical pharmacology forum: Motility agents and the gastrointestinal tract

American Journal of the Medical Sciences

Volumn 312, Issue 1, 1996, Pages 19-26

  Mccallum, Richard W ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8,9 ANHYDRO N ETHYLNORERYTHROMYCIN A 6,9 HEMIACETAL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BENZATROPINE MESILATE; BETHANECHOL; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLINERGIC RECEPTOR STIMULATING AGENT; CISAPRIDE; DEVAZEPIDE; DIPHENHYDRAMINE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; ERYTHROMYCIN; ERYTHROMYCIN ETHYLSUCCINATE; FEDOTOZINE; LEUPRORELIN; LOXIGLUMIDE; MACROLIDE; METOCLOPRAMIDE; MISOPROSTOL; NALTREXONE; NEOSTIGMINE; OCTREOTIDE; OPIATE AGONIST; PROKINETIC AGENT; RENZAPRIDE; SEROTONIN ANTAGONIST; TROPISETRON; UNINDEXED DRUG; ZACOPRIDE;

ABDOMINAL CRAMP; ANTIEMETIC ACTIVITY; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; ENTEROPATHY; GASTROESOPHAGEAL REFLUX; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; REVIEW; STOMACH EMPTYING; STOMACH PARESIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029950582     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199607000-00004     Document Type: Review

References (58)

1. Valenzuela JE. Dopamine as a possible neurotransmitter in gastric relaxation. Gastroenterology. 1971;71:1019-22.
2. Stadaas J, Aune S. Clinical trial of metoclopramide on post-vagotomy gastric stasis. Arch Surg. 1972;104:684-6.
3. Heitman P, Moler N. The effect of metoclopramide on the gastroesophageal junctional zone and distal esophagus in man. Scand J Gastroenterol. 1970;5:620-6.
4. Fink SM, Lange RC, McCallum RW. Effect of metoclopra;mide on normal and delayed gastric emptying in gastroesophageal reflux patients. Dig Dis Sci. 1983;28:1057-61.
5. Johnson AG. Gastroduodenal motility and synchronization. Postgrad Med J. 1973;49(Suppl 4):29-33.
6. Bright-Asare P, El Bassoussi M. Cimetidine, metoclopramide or placebo in the treatment of symptomatic gastroesophageal reflux. J Clin Gastroenterol. 1980;25:750-5.
7. McCallum RW, Ippoliti AF, Coon C, et al. A controlled trial of metoclopramide in symptomatic gastroesophageal reflux. N Engl J Med. 1977;296;354-7.
8. McCallum RW, Fink SM, Lerner E, et al. Effects of meto;clopramide and bethanechol on delayed gastric emptying present in gastroesophageal reflux patients. Gastroenterology. 1983;84: 1573-7.
9. McCallum RW, Fink SM, Einnan GR, et al. Metoclopramide in gastroesophageal reflux disease: Rationale for its use and re;sults of a double-blind trial. Am J Gastroenterol. 1984;79:165-72.
10. Loo FD, Palmer DW, Soergel KH, et al. Gastric emptying in patients with diabetes mellitus. Gastroenterology. 1983;86: 485-94.
11. Schade RR, Duas MC, Lhotsky DM, et al. Effect of meto;clopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig Dis Sci. 1985;30:10-15.
12. McCallum RW, Grill BB, Lange R, et al. Definition of a gastric emptying abnormality in patients with anorexia nervosa. Dig Dis Sci. 1985;30:713-22.
13. McCallum RW, Valenzuela G, Polepalle S, et al. Subcu;taneous metoclopramide in the treatment of symptomatic gas;troparesis: Clinical efficacy and pharmacokinetics. J Pharmacol Exp Ther. 1991;258:136-42.
14. Albibi R, McCallum RW. Metoclopramide: Pharmacology and clinical application. Ann Intern Med. 1983;98:86-95.
15. Brogden RN, Carmine AA, Heel RC, et al. Domperidone: A review of its pharmacological activity, pharmacokinetic and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an anti-emetic. Drugs. 1982;24:360-400.
16. Bron B, Massih L. Domperidone: A drug with powerful action on the lower esophageal sphincter pressure. Digestion. 1980;20: 375-8.
17. Albibi R, DuBovic S, Lange RC, et al. A dose response study of the effects of domperidone on gastric retention states in man. Am J Gastroenterol. 1982;77:679.
18. Horowitz M, Harding PE, Chatterton BE, et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci. 1985;30:1-9.
19. Koch KL, Stern RM, Stewart WR, et al. Gastric emptying and gastric myoelectrical activity in patients with diabetic gas;troparesis: Effect of long-term domperidone treatment. Am J Gastroenterol. 1989;84:1069-75.
20. VanNeuten JM, Schuurkes JAJ. Pharmacodynamics of cis;apride, a prokinetic agent with indirect cholinergic properties. Digestion. 1986;34:137.
21. Cooke HJ, Carey HV. The effects of cisapride on serotonin-evoked mucosal response in guinea pig ileum. Eur J Pharmacol. 1984;98:147-8.
22. Wallin L, Kruse-Anderson S, Madsen T, et al. Effect of cisapride on the gastro-oesophageal function in normal human subjects. Digestion. 1987;37:160-5.
23. McCallum RW, Prakash C, Campoli-Richards DM, et al. Cisapride: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and the therapeutic use as a pro;kinetic agent in gastrointestinal motility disorders. Drugs. 1988;36:652-81.
24. Coremans G, Janssens J, Vantrappen G, et al. Cisapride stimulates propulsive motility patterns in human jejunum. Dig Dis Sci. 1988;33:1512-19.
25. Lee KY, Chey WY, You CH, et al. Effect of cisapride on the motility of gut in dogs and colonic transit time in dogs and hu;mans. Gastroenterology. 1984;86:1157.
26. Krevsky B, Maurer AH, Malmud LS, et al. Cisapride ac;celerates colonic transit in patients with colonic inertia. Am J Gastroenterol. 1989;84:822-87.
27. Jian R, Ducrot F, Piedeloup C, et al. Measurement of gastric emptying in dyspeptic patients: Effects of a new gastrokinetic agent (cisapride). Gut. 1985;26:352-8.
28. McCallum RW. Cisapride: A new class of prokinetic agent. Am J Gastroenterol. 1991;86:135-52.
29. Muller-Lissner SA, Fraas C, Hartl A. Cisapride offsets do;pamine-induced slowing of fasting gastric emptying. Dig Dis Sci. 1986;31:807-10.
30. Horowitz M, Maddox A, Harding PE, et al. Acute and chronic effects of cisapride on gastric esophageal emptying in insulin-dependent diabetes mellitus. Gastroenterology. 1987;92: 1899-1907.
31. Champion MC, Gulenchyn K, Braaten J, et al. Cisapride improves symptoms and solid phase gastric emptying in diabetic gastroparesis (DGP). Diabetes. 1988;37(Suppl 1);84:37.
32. Stacher G, Bergmann H, Wiesnagrotzki S, et al. Intrave;nous cisapride accelerates delayed gastric emptying and increases antral contraction amplitude in patients with primary anorexia nervosa. Gastroenterology. 1987;92:1000-6.
33. Corinaldesi R, Stanghellini V, Raiti C, et al. Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut. 1987;28:300-5.
34. Richards RD, Valenzuela GA, Davenport KG, et al. Ob;jective and subjective results of a randomized, double-blind, pla;cebo controlled trial using cisapride to treat gastroparesis. Dig Dis Sci. 1993;38(5):811-16.
35. Abell TL, Camilleri M, DiMagno EP, et al. Cisapride is effective in the long-term treatment of gastric motor disorders. Gastroenterology. 1987;92:A1287.
36. DeCastecker JS, Ewing DJ, Clarke BF, et al. Double-blind placebo-controlled trial comparing cisapride and metoclopramide in diabetes with autonomic neuropathy. Digestion. 1986;34:148-9.
37. Tatsuta M, Iishi H, Nakaizumi A, et al. Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Al;imentary Pharmacology and Therapy 1992;6:221-228.
38. Peeters T, Matthijs, Depoortere I, et al. Erythromycin is a motilin receptor agonist. Am J Physiol. 1989;257:G470-4.
39. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med. 1990;322:1028-31.
40. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol. 1993;88: 203-7.
41. Kendall BJ, Weber FH, Samy NH, et al. Effect of a single dose of IV erythromycin on gastric emptying in chronic post-surgical gastroparesis. (Manuscript submitted for publication).
42. Mozwecz H, Pavel D, Pitrak D, et al. Erythromycin stearate as prokinetic agent in postvagotomy gastroparesis. Dig Dis Sci. 1990;35:902-5.
43. Itoh Z, Omura S. Motilide, a new family of macrolide com;pounds mimicking motilin. Dig Dis Sci. 1987;32:915.
44. Wald A, Van Thiel DH, Hoechstetter L, et al. Gastrointes;tinal transit: The effect of the menstrual cycle. Gastroenterology. 1981;80:1497-1500.
45. Mathias JR, Ferguson KL, Clench MH. Debilitating "func;tional" bowel disease controlled by leuprolide acetate, gonado;tropin-releasing hormone (GnRH) analog. Dig Dis Sci. 1989;34: 761-6.
46. Costall B, Naylor RJ. 5-Hydroxytryptamine: New receptors and novel drugs for gastrointestinal motor disorders. Scand J Gastroenterol. 1990;25:769-87.
47. 3 receptor antagonist) on gastric emp;tying of solid meal in normal subjects. Gut. 1988;29:1249-52.
48. Schang JC, Devroede G, Perrault R. Naloxone therapy in small intestinal obstruction: Preliminary results about two cases. Am J Gastroenterol. 1984;79:828.
49. Shillabeer G, Davison JS. Proglumide, a cholecystokinin an;tagonist, increases gastric emptying in rats. Am J Physiol. 1987;252:R353-60.
50. Soudah HC, Hasier WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325:1461-67.
51. Edmunds MC, Chen J, Lin Y, McCallum RW. The effect of octreotide on postprandial antral motility in patients with idiopathic gastroparesis. Gastroenterology 1994;106:A492. Abstract.
52. Misiewicz JJ, Waller SL, Kiley N. Effect of oral prosta;glandin E1 on intestinal transit in man. Lancet. 1969;1:648-51.
53. Fioramonti J, Staumont G, Garcia-Villar R, Bueno L. Ef;fect of sennosides on colon motility in dogs. Pharmacology. 1988;36:23-30.
54. Staumont G, Fioramonti J, Frexinos J, Bueno L. Changes in colonic motility induced by sennosides in dogs: Evidence of a prostaglandin mediation. Gut. 1988;29:1180-87.
55. Riviere PJ, Farmer SC, Burks TF, Porreca F. Prostaglan;din E2-induced diarrhea in mice: Importance of colonic secretion. J Pharm Exp Thera. 1991;256:547-52.
56. Rutgeerts P, Vantrappen G, Hiele M, Ghoos Y, Onkelinx C. Effect on bowel motility of misoprostol administered before and after meals. Aliment Pharmacol Ther. 1991;5:533-42.
57. Soffer EE, Metcalf A, Launspach J. Misoprostol is effective treatment for patients with severe chronic constipation. Dig Dis Sci. 1994;39:929-33.
58. Roarty TP, Chen JDZ, McCallum RW. Effects of misoprostol on postprandial segmental colonic motility in healthy volunteers and refractory chronic constipation. Gastroenterol. 1994;106: A559. Abstract.